Évolution de la prise en charge et du pronostic de l'infarctus du myocarde en France entre 1995 et 2000 : résultats des études USIK 1995 et USIC 2000

@article{Cambou2004volutionDL,
  title={{\'E}volution de la prise en charge et du pronostic de l'infarctus du myocarde en France entre 1995 et 2000 : r{\'e}sultats des {\'e}tudes USIK 1995 et USIC 2000},
  author={J. P. Cambou and Nicolas Danchin and Y. Boutalbi and Guy Hanania and Roger Humbert and Pierre Clerson and Laurent Vaur and P. Gu{\'e}ret and Didier Blanchard and N. Gen{\`e}s and Jean M. Lablanche},
  journal={Annales De Cardiologie Et D Angeiologie},
  year={2004},
  volume={53},
  pages={12-17}
}
6 Citations

References

SHOWING 1-10 OF 13 REFERENCES
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
TLDR
Long-term treatment with trandolapril in patients with reduced left ventricular function soon after myocardial infarction significantly reduced the risk of overall mortality, mortality from cardiovascular causes, sudden death, and the development of severe heart failure.
A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction.
TLDR
A strategy for reperfusion involving the transfer of patients to an invasive-treatment center for primary angioplasty is superior to on-site fibrinolysis, provided that the transfer takes two hours or less.
Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the "real world": one-year results from a nationwide French survey.
TLDR
The results of this large registry of real-world practice indicate no survival benefit for patients treated with primary angioplasty compared with those who received thrombolytic therapy.
...
1
2
...